LLY · 8-K · 20260805PR000077
Operating Expense Trends
ELI LILLY & Co · 2026-08-05 · Importance 73 · Surprise 66 · From source text
Q2 2026 research and development expense increased 14% to $3.819 billion, representing 17% of revenue, due to continued investment in early- and late-stage programs. Marketing, selling, and administrative expense rose 25% to $3.430 billion, primarily reflecting promotional activity for ongoing and planned launches. Acquired in-process research and development charges increased to $2.776 billion from $154 million, with $2.8 billion of charges primarily tied to the Orna Therapeutics and Ajax Therapeutics acquisitions.
Key facts
- Q2 2026 marketing, selling, and administrative expenses: $3,430 million, increased 25% versus prior year. source
- Q2 2026 operating income: $8,978 million, increased 31% versus Q2 2025. source
- Q2 2026 research and development expenses: $3,819 million, increased 14% and represented 17% of revenue. source
- Q2 2026 net interest expense: $(274) million versus $(209) million in Q2 2025. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | positive | realized | +9.2% | Q2 2026 operating income: $8,978 million, increased 31% versus Q2 2025. |
| net_income | negative | realized | -0.3% | Q2 2026 net interest expense: $(274) million versus $(209) million in Q2 2025. |